Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
26.03
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Friday Markets News
March 25, 2022
Methane leaks in the Permian Basin are 6 times higher than estimates.
Via
Talk Markets
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have
Via
Benzinga
Flood Helping Ukraine
March 24, 2022
Emerging markets are gaining as mature markets look risky.
Via
Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For February 17, 2022
February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
Via
Benzinga
The Sunday File for Nov. 21
November 21, 2021
Good news and bad - making up for the short week by getting a Sunday start.
Via
Talk Markets
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Futures Flat As Traders Brace For Op-Ex Volatility, More Ukraine Headlines
February 18, 2022
In the latest geopolitical developments Russian Foreign Minister Sergei Lavrov agreed to meet US Secretary of State Antony Blinken for talks in Europe next week; German Chancellor Olaf Scholz will host...
Via
Talk Markets
Exelixis: Q4 Earnings Insights
February 17, 2022
Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings...
Via
Benzinga
Earnings Preview For Exelixis
February 16, 2022
Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will...
Via
Benzinga
Analyst Ratings For Exelixis
November 03, 2021
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:
Via
Benzinga
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
February 15, 2022
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (...
Via
Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5%
January 10, 2022
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings...
Via
Benzinga
Early Monday Report - More Moves Out Of China
January 09, 2022
Before it even turned Monday in the West, China insurers are feeling the heat.
Via
Talk Markets
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now
January 03, 2022
These cheap stocks are trading at highly attractive prices and have the potential to break through this year.
Via
InvestorPlace
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Uncertain Times
December 15, 2021
The UK inflation rate last month was 5.1%, not a good omen.
Via
Talk Markets
3 No-Brainer Biotech Stocks to Buy in November
November 04, 2021
Here are three Motley Fool contributors' top picks.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 03, 2021
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript
November 02, 2021
EXEL earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis: Q3 Earnings Insights
November 02, 2021
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis...
Via
Benzinga
Exelixis Earnings Perspective: Return On Capital Employed
November 02, 2021
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Here's My Top Value Stock To Buy Right Now
November 01, 2021
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
Via
Talk Markets
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Down 76%: Is Cortexyme Stock a Bargain?
October 28, 2021
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
Via
The Motley Fool
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock
October 18, 2021
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.